Table 1

Data collection items

  • Authors, journal, year of publication, title of the article.

  • Study design.

  • Participants.

  • Sample size, loss to follow-up.

  • Characteristics of participants at baseline as age, sex, body mass index, cardiovascular comorbidities, cardiovascular risk factors, co-medications with influence on the cytochrome of interest, history of adverse reaction to multiple medications, lipid profile, past achievement of LDL-C goals; creatine kinase, liver function test, intolerance, SAMS.

Intervention and control
  • Statins, doses, timing, frequency, length of intervention, washout period, duration of follow-up.

  • Description of co-interventions, lifestyle modification, modification of baseline medication regimen.

  • Types of comparator, doses, timing, frequency, intervention protocols, length of intervention, washout period, duration of follow-up.

  • Proportion of population with/without muscles symptoms-related adverse events, time to muscles symptoms-related adverse events, proportion of population with muscles symptoms related drop out, lipid profile, creatine kinase level, liver function test.

  • Multiple adverse events occurrence in the same individuals.

  • All other adverse outcomes and collection systematic: definition of each adverse outcome addressed, method of ascertainment (patient report vs active search), method of measurement, timing and frequency of adverse events, measurement of the severity.

  • Associated factor to the adverse events.

  • For each outcome at each time point: number of participants randomly assigned and included in the analysis; number of participants who withdrew, were lost to follow-up or were excluded with reasons for each.

  • Conflicts of interest, funding sources.

  • SAMS, statin-associated muscle symptom.